Disorders of lipid metabolism

September 6-7, 2007 - San Diego, California, USA

• 2 days, 2 Chairpersons, 17 speakers, 81 learners, 0 commercial exhibitors, 7 posters presented.
• Learner type: 20% Scientists, 30% Clinicians, 31% Industry, 2% Nurses and 17% Other.
• Credit type: ACCME, ACPE.
• This symposium featured an international faculty of research leaders who presented their most current data highlighting the genetic basis of common lipid disorders including subjects such as diabetes, atherosclerosis, high-density lipoproteins and the metabolic syndrome.
• 100% of learners reported that the content was free from commercial bias.
• 100% of learners reported that the content was scientifically rigorous.
• 97% of learners reported that they would recommend this program to a colleague.
• Objectives of the course were to:
• Describe factors that influence HDL levels and HDL-related diseases.
• List genes and genetic factors involved in cardiovascular and metabolic diseases.
• Identify the cluster of components involved in determining metabolic risks and the metabolic syndrome.
• Discuss the metabolic pathways that are current therapeutic targets.

• There were 3 poster abstract awards: 1^st: $1000, 2^nd: $750, 3^rd: $500 that went to:

• Grand Prize: BioSymposia Junior Investigator Award to Poster Number P-05 titled “Oxidation-Specific Epitopes are a Major Target of Innate Natural Antibodies”, accepted by Meng-Yu Chou. Co-authors are J.L. Witztum and C.J. Binder from the University of California, San Diego, Department of Medicine and the Medical University of Vienna, The Institute of Medical and Chemical Laboratory Diagnostics.
• Second Prize: to Poster Number P-07, titled “Positional Cloning of a Novel Gene Involved in Lipase Maturation and Hyperlipidemia”, accepted by Miklos Peterfy from the University of California, Los Angeles, CA. Co-authors are Hui Z. Mao, Osnat Ben-Zeev, and Mark H. Doolittle of the VA Greater Los Angeles Healthcare Center. This research was supported by: National Institutes of Health Grant P01HL28481.

• Third Prize: to Poster Number P-04, titled “Adipose Tissue Expression of Stearoyl-CoA Desaturase Transcript is Correlated with Components of Atherogenic Dyslipidemia in Hypertriglyceridemic Men”, accepted by Lara Mangravite. Co-authors are Sally Chiu and Ronald M. Krauss from Children’s Hospital Oakland Research Institute, Oakland, CA. This research was supported by: National Institutes of Health (MD00222) and the National Dairy Council.

• Selected learner comments included:

• “As a clinician, I was quite impressed with all the speakers and their ability to clearly explain their research / expertise in basic science concepts.”
• “The meeting was stellar.”
• “Definitely recommend this program. Cutting edge research happening in early stages before tested in humans. Theories / hypotheses discussed were very interesting. Hopefully many will come to fruition so that our patients will benefit.”
• “Excellent speakers.”
• “Good size meeting for interaction.”
• “Great line-up of speakers.”
• “Excellent organization, excellent content.”
• “Excellent speakers and time for discussion after talks.”

• “Very well organized and learned a lot from such well-established scientists.

• Very inspiring.”

Disclosure of Faculty Relationships

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA), the Accreditation Council for Pharmaceutical Education (ACPE), and all other professional organizations as applicable, stating that programs where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

As uses for pharmaceutical agents, medical devices, and other products may be presented in the program that are not necessarily the same as those indicated in approved product labeling (but which may reflect clinical experience, professional literature, other clinical sources known to the presenter, or investigational uses of products), we ask the presenter to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is simply intended to inform participants of any potential conflicts so that participants may form their own judgments based on full disclosure of the facts. Further, these opinions and recommendations presented during the program or materials related to the program do not imply an endorsement or recommendation on the part of BioSymposia, Inc. These presentations solely represent the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-FDA approved (off-label) uses of drugs:

Alan M. Fogelman, M.D. discloses that he is a principal officer and major stockholder of Bruin Pharmaceuticals.

The following faculty indicated no significant relationship with commercial supporters and/or discussion of investigational or non-FDA approved (off-label) uses of drugs:

Alan Chait M.D., Robert A. Hegele, M.D., F.R.C.P.C., F.A.C.P., Alan D. Attie, Ph.D., Linda K. Curtiss, Ph.D., Peter A. Edwards, Ph.D., Christopher K. Glass, M.D., Ph.D., Ira J. Goldberg, M.D., Michael Hayden, M.B., Ch.B., Ph.D., F.R.C.P.(C), F.R.S.C., Jay W. Heinecke, M.D., Jay Horton, M.D., Murray W. Huff, Ph.D., Ronald M. Krauss, M.D., James M. Ntambi, Ph.D., Jose M. Ordovas, Ph.D., John F. Oram, Ph.D., Len A. Pennacchio, Ph.D., Philipp E. Scherer, Ph.D., Ulf Smith, M.D., Ph.D., F.R.C.P.(G), and Bart Staels, Ph.D.

Commercial Support and Other Disclosures

BioSymposia, Inc. (formerly Serono Symposia International, Inc.) is a 501(c)3 non-profit organization. All of our programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers and do not represent an endorsement or recommendation on the part of BioSymposia, Inc.

This program was supported by an unrestricted educational grant from EMD Serono, Inc. In addition, BioSymposia personnel are employees of EMD Serono, Inc. and BioSymposia, Inc. also receives other in-kind support from EMD Serono, Inc. in the form of space and administrative services.

This program was endorsed by the National Lipid Association.

The National Lipid Association is recognized to endorse the credit hours offered by this activity as “lipid-focused” continuing medical education that meets the credentialing and certification standards established by the American Board of Clinical Lipidology (www.lipidboard.org) and the Accreditation Council for Clinical Lipidology (www.lipidspecialist.org).

Printer friendly version Disorders Of Lipid Metabolism